Compare SBLK & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBLK | TLX |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | Greece | Australia |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.2B |
| IPO Year | 2007 | N/A |
| Metric | SBLK | TLX |
|---|---|---|
| Price | $24.91 | $10.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $22.00 | $21.13 |
| AVG Volume (30 Days) | ★ 968.4K | 219.4K |
| Earning Date | 05-13-2026 | 08-19-2026 |
| Dividend Yield | ★ 2.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.56 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $47.06 | $150.33 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.92 | $6.28 |
| 52 Week High | $27.20 | $19.93 |
| Indicator | SBLK | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 59.68 | 68.84 |
| Support Level | $21.71 | $10.60 |
| Resistance Level | $27.20 | $11.28 |
| Average True Range (ATR) | 0.75 | 0.33 |
| MACD | 0.11 | 0.05 |
| Stochastic Oscillator | 82.13 | 69.88 |
Star Bulk Carriers Corp provides seaborne transportation solutions in the dry bulk sector. The company owns and operates dry bulk carrier vessels, which are used to transport bulk, such as iron ore, coal, grains, bauxite, fertilizers, and steel products. It owns a fleet of vessels that consists of Newcastlemax, Capesize, Post Panamax, Kamsarmax, Panamax, Ultramax, and Supramax. The firm generates the majority of its revenue from Time charters and Voyage charters.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.